DLL3 and small cell lung carcinoma: Tarlatamab is a first-in-class, half-life extended bispecific antibody delta-like ligand 3 (DLL3)-directed CD3 T cell engager indicated for the treatment of adult patients presenting advanced stage small cell lung cancer (ES-SCLC) with disease progression during or after platinum-based chemotherapy.